Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study
K. B. Weiss, M. Buxton, L. F. Andersson, C. J. Lamm, B. Liljas, P. M. O‘Byrne, W. C. Tan, S. D. Sullivan (Chicago, Seattle, United States Of America; Uxbridge, United Kingdom; Basel, Sweden; Hamilton, Canada; Singapore, Singapore)
Source: Annual Congress 2003 - Advances in our understanding of corticosteroids in the treatment of asthma
Disease area: Airway diseases, Paediatric lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. B. Weiss, M. Buxton, L. F. Andersson, C. J. Lamm, B. Liljas, P. M. O‘Byrne, W. C. Tan, S. D. Sullivan (Chicago, Seattle, United States Of America; Uxbridge, United Kingdom; Basel, Sweden; Hamilton, Canada; Singapore, Singapore). Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study. Eur Respir J 2003; 22: Suppl. 45, 339
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Effectiveness of early intervention with budesonide in mild persistent asthma — 5-year data from the START study Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004
Long-term safety data with once-daily budesonide in mild asthma: results from the START study Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
The effects of early intervention with inhaled budesonide on lung function in mild persistent asthma: results from the START study Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
The cost-effectiveness of early intervention with inhaled budesonide once daily: an international comparison of the results from the START study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002
Fracture rate in patients with asthma receiving long-term early intervention with budesonide: the START study Source: Eur Respir J 2005; 26: Suppl. 49, 276s Year: 2005
Country-specific cost-effectiveness of early intervention with budesonide in mild asthma Source: Eur Respir J 2004; 24 : 568-574 Year: 2004
Follow-up results 10 years after early intervention with budesonide or terbutaline in mild persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 667s Year: 2006
Cost-effectiveness of early intervention with budesonide once daily: Results from the START study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002
High or standard initial dose of budesonide to control mild-to-moderate asthma? Source: Eur Respir J 2001; 17: 856-862 Year: 2001
Comparative study of 8-weeks treatment of asthma exacerbations in adults with high doses of budesonide versus fluticasone Source: Eur Respir J 2001; 18: Suppl. 33, 97s Year: 2001
Early intervention with budesonide in mild persistent asthma - the START study. On behalf of the START investigators group Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002
Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021
Comparison of the efficacy of cicleosonide with budesonide in mild to moderate asthma patients after step-down therapy Source: Annual Congress 2011 - Asthma management and response Year: 2011
Intermittent tiotropium in early childhood wheezing? Preliminary safety results of a pilot study Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
Tolerability and efficacy of budesonide/formoterol via Turbuhaler® vs standard treatment in Japanese patients with moderate to severe COPD: 52-week phase III study results Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012
Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002
Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1-year study Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Efficacy of the using budesonide/formoterol in patients with bronchial asthma (BA): the study of routine clinical practice Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006